Domenica Lorusso, Y. Xiang, Kosei Hasegawa, G. Scambia, Manuel Leiva, Pier Ramos-Elias, A. Acevedo, J. Vizkeleti, A.J.P.D.S. Gomes, Fernando Contreras Mejia, A. Reiss, Ali Ayhan, Jung-Yun Lee, V. Saevets, F. Zagouri, Kan Li, Karin Yamada, Sarper Toker, Sandro Pignata, L. Duska
{"title":"161 Pembrolizumab 联合化放疗治疗高风险局部晚期宫颈癌:随机、双盲、3 期 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 研究","authors":"Domenica Lorusso, Y. Xiang, Kosei Hasegawa, G. Scambia, Manuel Leiva, Pier Ramos-Elias, A. Acevedo, J. Vizkeleti, A.J.P.D.S. Gomes, Fernando Contreras Mejia, A. Reiss, Ali Ayhan, Jung-Yun Lee, V. Saevets, F. Zagouri, Kan Li, Karin Yamada, Sarper Toker, Sandro Pignata, L. Duska","doi":"10.1136/ijgc-2024-esgo.3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"19 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study\",\"authors\":\"Domenica Lorusso, Y. Xiang, Kosei Hasegawa, G. Scambia, Manuel Leiva, Pier Ramos-Elias, A. Acevedo, J. Vizkeleti, A.J.P.D.S. Gomes, Fernando Contreras Mejia, A. Reiss, Ali Ayhan, Jung-Yun Lee, V. Saevets, F. Zagouri, Kan Li, Karin Yamada, Sarper Toker, Sandro Pignata, L. Duska\",\"doi\":\"10.1136/ijgc-2024-esgo.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"19 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study